Serious Infections in Offspring Exposed in Utero to Vedolizumab.

Controlling IBD during pregnancy is important for maternal and fetal outcomes. We created a cohort of children born to mothers with IBD, comparing the risk of infections in those exposed to vedolizumab vs unexposed. We detected no increased risk.

[1]  N. Uldbjerg,et al.  Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study , 2021, Alimentary pharmacology & therapeutics.

[2]  A. Amiot,et al.  Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study , 2020, Alimentary pharmacology & therapeutics.

[3]  M. Dubinsky,et al.  Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease. , 2020, Gastroenterology.

[4]  G. Guyatt,et al.  2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases , 2020, Arthritis & rheumatology.

[5]  S. Vermeire,et al.  Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study , 2020, Alimentary pharmacology & therapeutics.

[6]  G. Shaw,et al.  Data-driven queries between medications and spontaneous preterm birth among 2.5 million pregnancies. , 2019, Birth defects research.

[7]  S. Hernández-Díaz,et al.  Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance , 2019, Pharmacoepidemiology and drug safety.

[8]  M. Dubinsky,et al.  Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. , 2019, Inflammatory bowel diseases.

[9]  J. Andrews,et al.  Letter: vedolizumab drug concentrations in neonates following intrauterine exposure , 2018, Alimentary pharmacology & therapeutics.

[10]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[11]  A. Forster,et al.  Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. , 2014, Journal of clinical epidemiology.

[12]  P. Tekkis,et al.  A meta-analysis on the influence of inflammatory bowel disease on pregnancy , 2006, Gut.